不同腔内主动脉瘤修复方式及器械植入后综合征发生率与病因学意义
这项单中心回顾性研究比较了腹主动脉瘤腔内隔绝术(EVAS)与腔内修复术(EVAR)后植入后综合征(PIS)的发生率。2013年1月至2018年6月,60例患者接受EVAS,110例接受EVAR(其中56例使用AFX器械,54例使用其他PTFE覆膜支架)。结果显示EVAS组PIS发生率显著低于EVAR组(8.3% vs 30% vs 35%,P=0.001),提示新发附壁血栓可能在PIS发生中起作用。
要点
- EVAS术后PIS发生率显著低于EVAR,可能与Nellix系统完全封闭瘤囊、减少新发附壁血栓有关。
- 使用AFX内骨架器械与其他外骨架PTFE覆膜支架的EVAR术后PIS发生率无显著差异。
- 随访期间,有无PIS患者的主要不良事件发生率无显著差异(8.0% vs 13.4%,P=0.43)。
核心结论
- EVAS术后PIS风险低于EVAR,新发附壁血栓可能在PIS发生中起重要作用。
- AFX内骨架器械与其他EVAR外骨架覆膜支架的全身炎症反应无显著差异。
- PIS对早期主要不良事件无显著预后影响。
研究设计与样本
- 单中心回顾性研究,纳入2013年1月至2018年6月60例接受EVAS的AAA患者(平均年龄72±9岁)和110例接受EVAR的患者(56例AFX器械,54例其他PTFE覆膜支架;平均年龄74±10岁)。
主要发现
- EVAS组PIS发生率为8.3%,AFX组为30%,其他覆膜支架组为35%,三组比较P=0.001。
- 随访期间主要并发症发生率:EVAS组10.3%,EVAR组(AFX 8.9%,其他16.4%),组间比较P=0.43。
- 随访(平均24个月)期间,有无PIS患者的不良结局发生率分别为8.0%和13.4%,P=0.43。
临床怎么用
- 临床选择EVAR器械时可考虑PIS风险,EVAS可能降低PIS发生率。
- PIS似乎不影响早期主要不良事件,但仍需关注术后炎症反应。
局限性
- 回顾性单中心设计,样本量有限(EVAS 60例,EVAR 110例),随访时间平均24个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postimplantation syndrome (PIS) is a systemic inflammatory response occurring in an early phase after abdominal aortic aneurysm (AAA) endovascular aneurysm repair (EVAR). The pathophysiology underlying PIS is still not well understood. It is speculated that the type of the stent graft or the mural thrombus within the AAA may play a role in determining this inflammatory response. At present, there is no consensus about the influence of PIS on clinical outcomes during follow-up. The endovascular aneurysm sealing (EVAS) with the Nellix sac-anchoring endoprosthesis (Nellix Endovascular, Palo Alto, CA) is a novel modality for AAA repair, which obliterates the sac, thus preventing the new onset of thrombus in the aneurysm sac. Our aim was to compare the incidence of postimplantation syndrome following EVAS and after EVAR. Secondary aims were to assess the effect of endoskeleton AFX (Endologix) device compared with other commercially available exoskeleton PTFE stent grafts on the inflammatory response. Finally, we analyzed the potential association of PIS with clinical outcomes. METHODS: From January 2013 to June 2018, 60 AAA patients underwent EVAS (mean age 72 ± 9 years), and 110 patients were submitted to EVAR: 56 AFX devices and 54 other PTFE stent grafts (mean age 74 ± 10 years) at a single center and were retrospectively reviewed. RESULTS: EVAS with the Nellix system was associated with a lower incidence of PIS compared to EVAR using both AFX device and other endografts (8.3, 30, 35%, respectively, P-value = 0.001). No statistically significant difference in PIS incidence was observed after endoskeleton AFX device deployment compared with other EVAR exoskeleton endografts. During follow up, the major complications were proportionally but not significantly (P = 0.43) less frequent after EVAS (10.3%) than after EVAR and after EVAR using AFX device (8.9%) than after EVAR with other PTFE stent grafts (16.4%). During follow up (mean 24 months), adverse outcome rates did not significantly differ in patients with and without PIS (8.0 vs. 13.4% P = 0.43). CONCLUSIONS: Our data confirm the lower risk of PIS following EVAS compared to EVAR. Most importantly, this study highlights the role of new-onset mural thrombus in the genesis of PIS. The lower inflammatory reaction observed after EVAS than after EVAR might be related to the endobags of the Nellix system, which completely seal the aneurysm sac, reducing the new onset of mural thrombus. The systemic inflammatory response does not significantly differ after endoskeleton AFX device deployment compared with other EVAR exoskeleton stent grafts. PIS does not seem to have any significant prognostic implications in terms of early major adverse events.
引用
- Martinelli O, Di Girolamo A, Belli C, et al. Incidence of Post-Implantation Syndrome with Different Endovascular Aortic Aneurysm Repair Modalities and Devices and Related Etiopathogenetic Implications. Ann Vasc Surg. 2019. PMID: 31629127. doi:10.1016/j.avsg.2019.08.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。